However, in a retrospective analysis of 58 patients with NSCLC treated with PD-1/PD-L1 inhibitors, the response rate was 3.6% in the EGFR mutation or ALK fusion subgroups and 23.3% in the wild-type subgroups (27). The gene discussed is ALK; the disease is non-small cell lung carcinoma.